Pyxis Oncology (PYXS) Liabilities and Shareholders Equity (2020 - 2026)

Pyxis Oncology (PYXS) has reported Liabilities and Shareholders Equity for 6 consecutive years, with $91.5 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity fell 41.77% year-over-year to $91.5 million; the TTM figure through Dec 2025 stood at $456.2 million (down 41.59% YoY), while the FY2025 annual figure was $91.5 million, down 41.77% from the prior year.
• Liabilities and Shareholders Equity declined to $91.5 million in Q4 2025 per PYXS's latest filing, from $105.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $280.0 million in Q4 2021 and bottomed at $91.5 million in Q4 2025.
• Historically, Liabilities and Shareholders Equity has averaged $183.7 million across 5 years, with a median of $184.7 million in 2023.
• Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity jumped 2658.56% — and 2025, when it tumbled 45.93%.
• Pyxis Oncology's Liabilities and Shareholders Equity stood at $280.0 million in 2021, then fell by 24.51% to $211.4 million in 2022, then dropped by 17.81% to $173.7 million in 2023, then dropped by 9.52% to $157.2 million in 2024, then tumbled by 41.77% to $91.5 million in 2025.
• Business Quant data shows PYXS's Liabilities and Shareholders Equity at $91.5 million in Q4 2025, $105.6 million in Q3 2025, and $123.2 million in Q2 2025.